Patent application number | Description | Published |
20080213165 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods - The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A | 09-04-2008 |
20080248112 | USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES - Disclosed are methods for treating patients suffering from coronary microvascular disease comprising administering ranolazine to the patient. In one embodiment, ranolazine is administered as an oral dose | 10-09-2008 |
20080255031 | METHOD FOR ENHANCING INSULIN SECRETION - The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent. | 10-16-2008 |
20090081120 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods - The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A | 03-26-2009 |
20090118221 | METHOD OF TREATING ARRHYTHMIAS - Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A | 05-07-2009 |
20090203689 | ABCA-1 ELEVATING COMPOUNDS AND METHODS - Disclosed are novel compounds of Formula I | 08-13-2009 |
20090203707 | METHODS FOR TREATING PAIN - This invention relates to methods for treating a patient suffering from neuropathic or nociceptive pain which may be mechanical, visceral, and/or inflammatory in nature, comprising administering a therapeutically effective amount of Ranolazine to a patient in need thereof. | 08-13-2009 |
20090312340 | USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients. | 12-17-2009 |
20100004255 | METHOD OF TREATING ARRHYTHMIAS - Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects. | 01-07-2010 |
20100056536 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 03-04-2010 |
20100086483 | METHOD OF MULTIDETECTOR COMPUTED TOMAGRAPHY - This invention relates to methods for multidetector computed tomography myocardial perfusion imaging comprising administering doses of a rate-control agent and one or more adenosine A | 04-08-2010 |
20100105695 | METHOD FOR ENHANCING INSULIN SECRETION - The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent. | 04-29-2010 |
20100105706 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS - The present invention relates to methods of preventing airway remodeling using A | 04-29-2010 |
20100130436 | CO-ADMINISTRATION OF RANOLAZINE AND CARDIAC GLYCOSIDES - The present invention relates to a method for reducing the toxicity of cardiac glycosides comprising the coadministration of a therapeutically effective amount of cardiac glycoside and a therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 05-27-2010 |
20100158797 | USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A | 06-24-2010 |
20100160620 | N-PYRAZOLE A2A RECEPTOR AGONISTS - 2-adenosine N-pyrazole compounds having the following formula: | 06-24-2010 |
20100183503 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 07-22-2010 |
20100292217 | RANOLAZINE FOR THE TREATMENT OF CNS DISORDERS - The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine. | 11-18-2010 |
20110144320 | N-PYRAZOLE A2A RECEPTOR AGONISTS - 2-adenosine N-pyrazole compounds having the following formula: | 06-16-2011 |
20110183990 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 07-28-2011 |
20110184002 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS - The invention is related to methods of preventing and treating hepatic fibrosis using A | 07-28-2011 |
20120003329 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension - This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A | 01-05-2012 |
20120004188 | USE OF RANOLAZINE FOR TREATING PULMONARY HYPERTENSION - This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient. | 01-05-2012 |
20120046299 | METHOD OF TREATING ARRHYTHMIAS - Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects. | 02-23-2012 |
20120189538 | USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A | 07-26-2012 |
20120195827 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 08-02-2012 |
20120220608 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS - The invention is related to methods of preventing and treating hepatic fibrosis using A | 08-30-2012 |
20120251440 | METHODS OF MYOCARDIAL PERFUSION IMAGING - The present invention provides a method for identifying and using partial adenosine A | 10-04-2012 |
20120258974 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS - Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A | 10-11-2012 |
20120269898 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION - Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations. | 10-25-2012 |
20130058866 | N-PYRAZOLE A2A RECEPTOR AGONISTS - 2-adenosine N-pyrazole compounds having the following formula: | 03-07-2013 |
20130317038 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 11-28-2013 |
20130343987 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 12-26-2013 |
20140073596 | N-Pyrazole A2A Receptor Agonists - 2-adenosine N-pyrazole compounds having the following formula: | 03-13-2014 |
20140221286 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION - It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers. | 08-07-2014 |
20140243358 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS - The invention is related to methods of preventing and treating hepatic fibrosis using A | 08-28-2014 |
20140275098 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION - Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations. | 09-18-2014 |
20140323493 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 10-30-2014 |
20140329755 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE - The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late I | 11-06-2014 |
20140364417 | METHOD OF TREATING ATRIAL FIBRILLATION - The present disclosure relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a therapeutically effective amount of ivabradine or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of ranolazine. Also provided are methods for modulating ventricular and atrial rate. This disclosure also relates to pharmaceutical formulations that are suitable for such combined administration. | 12-11-2014 |
20150023867 | METHODS OF MYOCARDIAL PERFUSION IMAGING - The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide. | 01-22-2015 |
20150038487 | METHODS OF TREATING HYPERTROPHIC CARDIOMYOPATHY - The present disclosure relates to a compound of formula (I) or formula (II) | 02-05-2015 |
20150038489 | COMPOUND AND METHODS FOR TREATING LONG QT SYNDROME - Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker | 02-05-2015 |
20150045305 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS - Described herein is a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising administration of an effective amount of one or more of a potassium channel blocker and an effective amount of one or more of a late sodium channel blocker. Also provided are methods for modulating ventricular and atrial rhythm and rate. Also provided are pharmaceutical formulations that are suitable for such combined administration. | 02-12-2015 |